Design and created by Guideline Central in participation with the American Society of Clinical Oncology and Cancer Care Ontario.
Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
American Society of Clinical Oncology
Cancer Care Ontario
Publication Date: January 17, 2022
Recommendation Grading
Abbreviations
- ASCO
- American Society of Clinical Oncology
- CCO
- Cancer Care Ontario
- HER2
- Human Epidermal Growth Factor Receptor 2
- OH
- Ontario Health
- ONJ
- osteonecrosis of the jaw
- OS
- overall survival
Source Citation
Eisen A, Somerfield MR, Accordino MK, et al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol. 2021 Jan 18. doi:10.1200/JCO.21.02647
Disclaimer
This pocket guide is derived from recommendations in the American Society of Clinical Oncology Guideline. This resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. The practice guidelines and additional information are available at www.asco.org/breast-cancer-guidelines. Copyright © 2021 by American Society of Clinical Oncology. All rights reserved.
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.